Fridtjof Lund-Johansen, KG Jebsen Center for Cancer Immunotherapy, Department of Immunology, Oslo University Hospital, Rikshospitalet
Fridtjof Lund-Johansen, MD, PhD is leading a group working on array-based protein analysis at the KG Jebsen Center for Cancer Immunotherapy at the Oslo University Hospital. Their goal is to make proteomics simple and accessible. In Microsphere Affinity Proteomics (MAP) biotinylated sample proteins are captured onto bead-based antibody arrays and detected by flow cytometry. MAP has a multiplexing capacity similar to that of mass spectrometry (MS) but the throughput is at least two orders of magnitude higher. His recent work has focused on antibody validation and multiplexed versions of the western blot. The next step is MAP assays to analyze proteins and protein complexes in subcellular compartments. They are also developing a MAP array with thousands of recombinant human proteins. The MAP protein array is used to test the specificity of antibodies to human proteins and to screen for autoantibodies in serum from patients with auto-immune disease and cancer. This combination will be a game changer in antibody validation and protein detection. Lund-Johansen and co-workers have published work on MAP technology published in Science (2016), Molecular&Cellular Proteomics (2009, 2016), Proteomics (2011), New Biotechnology (2012) and Cytometry (2012). More recently, the group has published new bioinformatics for subcellular proteomics (Nature Methods 2016) and antibody validation (Nature Methods 2018).
Host: Janne Lehtiö
Time: 1330-1430, March 21
Location: Gamma 2 Lunchroom